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Symptomatic hyperlactataemia in adults on antiretroviral 
therapy: A single-centre experience
June Fabian, Willem D F Venter, Louisa Mkhabela, Jonathan B Levin, Lee Baker, Saraladevi Naicker
The use of nucleoside reverse transcriptase inhibitors (NRTIs) 
in combination with other antiretroviral drugs in a schedule 
of antiretroviral therapy (ART) is considered standard-of-
care for those living with HIV.1-3 ART has led to significant 
decreases in morbidity and mortality, compared with untreated 
HIV-infected patients. This benefit also extends to those in 
developing countries.1,2
Public sector access to ART was initiated in 2004 in South 
Africa. The recommended first-line regimen comprises 
two NRTIs in combination with a non-nucleoside reverse 
transcriptase inhibitor (NNRTI).4 The combination most 
frequently used is stavudine, lamivudine and efavirenz 
(‘regimen 1a’). Nevirapine is recommended instead of efavirenz 
(owing to teratogenicity concerns) for women of child-bearing 
potential (‘regimen 1b’). ‘Regimen 2’ includes the combination 
of didanosine, zidovudine and lopinavir/ritonavir. Criteria for 
initiation of ART in the public sector for adults and adolescents 
are CD4 <200 cells/µl irrespective of clinical stage, or World 
Health Organization stage IV illness irrespective of CD4 count.4
Several serious ART-related complications have been noted 
in the era of chronic, effective treatment, including NRTI-
related symptomatic hyperlactataemia. At present, although 
more is understood regarding its pathogenesis, the best 
treatment is a high index of clinical suspicion, early detection 
and prompt cessation of the offending agents.5-7
We performed a retrospective review of records from a large 
clinic in Johannesburg to identify the incidence of symptomatic 
hyperlactataemia and its risk factors.
Methods
Study population
Johannesburg Hospital runs a large ART outpatient clinic. We 
retrospectively reviewed the records of all patients attending 
the outpatient clinic, and extracted data from those with 
documented symptomatic hyperlactataemia for the period  
1 January 2004 to 31 December 2005. Data included race, age 
and gender of all patients and, in those with hyperlactataemia, 
weight, details of antiretroviral drug history, CD4 cell count, 
viral load, clinical signs, symptoms and events, and relevant 
blood tests. Testing for hyperlactataemia is only performed 
if clinically indicated, and routine screening is not done. 
Death was defined as in-hospital mortality. Lactic acidosis 
was defined as pH <7.35, bicarbonate <20 mmol/l and raised 
lactate (>5.0 mmol/l). Severe hyperlactataemia was defined 
as a lactate measurement >5.0 mmol/l and therefore includes 
lactic acidosis.8 Those with lactate ≤5.0 mmol/l and other 
potential causes for hyperlactataemia were excluded.
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Objective. There are limited data on symptomatic 
hyperlactataemia caused by antiretroviral therapy (ART) 
in resource-limited settings. We assessed individuals who 
developed symptomatic hyperlactataemia on ART in an 
outpatient clinic in South Africa.
Design. A retrospective record review was performed on 
patients attending the clinic from January 2004 to December 
2005.
Results. Thirty-five patients, all on stavudine-containing 
regimens, developed symptomatic hyperlactataemia. The 
incidence in this population was 20.5 cases per 1 000 person-
years of ART with an associated mortality of 21%. The major 
risk factor was being female (risk ratio (RR) 3.27). Significant 
clinical symptoms preceding symptomatic hyperlactataemia 
include nonspecific gastrointestinal symptoms, weight loss, 
and development of symptomatic neuropathy.
Conclusions. The incidence of symptomatic hyperlactataemia 
in our population was high. Simple clinical measures, such as 
neuropathy symptoms and monitoring of weight, may alert 
the clinician to impending symptomatic hyperlactataemia. 
Early diagnosis expedites safe outpatient care and switching 
of ART regimens without interruption, in many cases.
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The study was approved by the Human Research Ethics 
Committee, University of the Witwatersrand (protocol number 
M0500933).
Statistical analysis
Data were exported to the statistical package Stata Release 
8.0 for analysis. Descriptive analyses were carried out with 
continuous variables being summarised using means, standard 
deviations, medians, interquartile ranges and ranges; in 
some cases, 95% confidence intervals (CIs) for the mean were 
calculated. Categorical variables were summarised using 
frequencies and percentages of non-missing values.
Results
For the time period under review (1 January 2004 -  
31 December 2005), a total of 2 587 patients >18 years were 
initiated on ART; 1 674 (65%) were females and 913 (35%) were 
males. A total of 39 patients with lactate levels >5.0 mmol/l 
were identified. Of these, 4 were excluded: a 27-year-old 
woman with sepsis, haemolytic anaemia and jaundice; a 23-
year-old woman with diarrhoea; a 30-year-old woman with a 
history of lactic acidosis in 2003 on dual regimen didanosine 
and stavudine (she interrupted therapy for 11 months, was 
recommenced on stavudine, and died from Pneumocystis 
jirovecii pneumonia immune reconstitution inflammatory 
syndrome); and the fourth patient because no clinic records 
were found. Of the remaining 35 patients, 5 (14%) were male, 
30 (86%) female and 34/35 were black (Table I).
ART choice and ART-related side-effects before 
onset of symptomatic hyperlactataemia
Of all patients in the clinic, 82.6% were started on stavudine, 
lamivudine and efavirenz; 10.4% on stavudine, lamivudine and 
nevirapine; 0.8% on zidovudine, didanosine and lopinavir/
ritonavir; and 6.2% on various combinations. Of the 35 patients 
who developed symptomatic hyperlactataemia, all were 
on a stavudine-containing regimen, with 3 on a stavudine-
didanosine combination. This latter combination was the most 
affordable NRTI treatment available before the State ART 
programme, and some patients and clinicians elected not to 
change if viral suppression was achieved and the combination 
well tolerated. In those with symptomatic hyperlactataemia, 2 
males developed gynaecomastia without other symptoms of 
lipodystrophy; 8 patients experienced onset of a symptomatic 
neuropathy after commencement of ART; and 1 patient 
developed acute pancreatitis followed 6 months later by 
admission for frank diabetic ketoacidosis (no prior diagnosis of 
diabetes mellitus).
Symptoms at the time of the symptomatic 
hyperlactataemia
Most patients presented with nonspecific symptoms. 
Gastrointestinal complaints were the most common: epigastric/
abdominal pain, vomiting, loss of appetite, loss of weight, 
nausea, diarrhoea, heartburn and dyspepsia. Cardiorespiratory 
complaints were documented as shortness of breath, cough, 
chest pain and palpitations. Neuropsychiatric symptoms 
included neuropathy, dizziness and depressed mood. Other 
symptoms were bipedal oedema, cramping, and swelling of 
hands/fingers.
Features on clinical examination and 
laboratory findings at the time of symptomatic 
hyperlactataemia (Table II)
One patient gained weight; 4 had stable weights when 
compared with their measured weights from preceding visits. 
There was no record of preceding weights in 7 patients. 
Twenty-three patients lost weight before their presentation; the 
objective weight loss in 2 of these patients was not recorded. In 
the remaining 21 patients, mean weight loss was 4.75 kg (95% 
CI 2.28 - 7.22). Many patients started losing weight several 
visits before the diagnosis of symptomatic hyperlactataemia. 
Symptoms suggestive of neuropathy were evident in 13 
of 35 patients (37%); 17 of 35 patients had no features of a 
neuropathy (49%); and there was no documentation in 5 cases 
(14%). Baseline venous lactate level used for the purpose of this 
analysis was the first lactate taken to make the diagnosis. Peak 
venous lactate levels, where known, have been included as this 
parameter has been shown to be a poor prognostic marker.9
Outcome
One patient was lost to follow-up. Twelve out of 34 (35%) were 
treated as outpatients, all of whom survived. Twenty-two out 
of 34 (65%) were inpatients, of whom 7 died. Of those who 
died, 2 were admitted to the intensive care unit for multiple 
organ failure and received dialysis support. No other patients 
were dialysed. The median duration of admission, from 
data available for 19 patients, was 11 days (range 1 - 21). The 
overall mortality was 21% (7/34). Of those who died, 5/7 
(71%) had peak venous lactate levels >10 mmol/l compared 
with those who survived, of whom only 8/27 (30%) had peak 
venous lactate levels >10.0 mmol/l. The survival rate among 
the remaining 27 patients was 100% after a mean follow-up 
of 26.7 weeks. Twelve (45%) were successfully changed from 
stavudine to zidovudine with no recurrence of symptoms. Six 
of these were successfully switched as outpatients with no 
interruption. Of all patients in the clinic who were commenced 
on ART during the review period, 30/1 674 women 
(1.79%) and 5/913 men (0.55%) developed symptomatic 
hyperlactataemia. The relative risk in this study of women 
developing symptomatic hyperlactataemia compared with men 
was therefore 3.27 (95% CI 1.27 - 8.41).
Discussion
To our knowledge, this is the largest published series of 
symptomatic hyperlactataemia from a single site. However, 
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there have been large numbers of anecdotal reports in our 
region,10,11 leading to local guidelines for the treatment of this 
condition.12 A study in Uganda reported low rates (0.5%) of 
lactic acidosis with similar ART regimens.13
Table I. Descriptive data for 35 patients with symptomatic hyperlactataemia
Patients with symptomatic hyperlactataemia       Data
Gender
Female*          30
Male           5
Race
Black African          34
White           1
Age (years)
Mean (95% CI)          40.5 (37.6 - 43.5)
Standard deviation         8.7
Median (IQR)          41 (36 - 45)
Range           26 - 70
Weight† at diagnosis (kg)
Mean (95% CI)          72.1 (66.7 - 77.6)
Standard deviation         15.5
Median (IQR)          72 (59 - 85.5)
Range           42 - 94.2
Duration of cumulative ART exposure prior to symptomatic hyperlactataemia‡(months)
Mean (95% CI)          9.1 (8.2 - 9.9)
Standard deviation         2.4
Median (IQR)          9 (8 - 11)
Range           2 - 13
Nadir CD4 count§ (x106/l) prior to commencement of ART
Mean (95% CI)          79.8 (63.6 - 96.0)
Standard deviation         40.1
Median (IQR)          82 (44 - 109)
Range           8 - 166
CD4 count at time of symptomatic hyperlactataemia (x106/l)
Mean (95% CI)          229.1 (191.6 - 266.7)
Standard deviation         109.3
Median (IQR)          210 (159 - 254)
Range           34 - 567
Change in CD4 from nadir
Mean (95% CI)          142.2 (103.8 - 180.5)
Standard deviation         95.0
Median (IQR)          129.5 (84 - 213)
Range           0 - 401
ART regimen at time of symptomatic hyperlactataemia¶
Regimen 1a (d4T, 3TC,  EFV)         30 (85%)
Regimen 1b (d4T, 3TC, NVP)         2 (6%)
ddI + d4T          2 (6%)
ddI, d4T, EFV          1 (3%)
Viral load at time of symptomatic hyperlactataemia11
<400 copies/ml          30 (88.2%)
760 copies/ml          1 (2.9%)
2 560 copies/ml          1 (2.9%)
5 170 copies/ml          1 (2.9%)
133 000 copies/ml         1 (2.9%)
*No females were known to be pregnant at the time of symptomatic hyperlactataemia.
†Data from 3/35 cases unknown.
‡Data from 3/35 cases unknown.
§Data from 9/35 cases unknown.
¶3TC = lamivudine; d4T = stavudine; EFV = efavirenz; NVP = nevirapine; ddI = didanosine.
ııData from 1/35 cases unknown.
IQR = interquartile range.
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Symptomatic hyperlactataemia/lactic acidosis is part of 
the spectrum of mitochondrial toxicity associated with NRTI 
therapy. It has been reported in persons receiving both single- 
and dual-NRTI regimens.5-7,14 The quoted incidence of lactic 
acidosis varies, depending upon definitions used, but ranges 
from 1.3 to 25.2 cases per 1 000 person-years of ART.15 The 
incidence of symptomatic hyperlactataemia in this study was 
20.5 cases per 1 000 person-years of ART. ‘Threshold’ lactate 
levels are proposed by some as a prognostic marker. In one 
study, lactate levels of ≥9 mmol/l were associated with a 
positive predictive value for death of 81.82% and a negative 
predictive value of 94.44%. Others have used a ‘threshold’ of 
≥10 mmol/l to predict mortality ranging from 60% to 80%.16 
In our series, a lactate >10 mmol/l was associated with a 
mortality of 71%.
Stavudine and didanosine are the most frequent NRTIs 
implicated in mitochondrial toxicity. The combination of 
stavudine and didanosine is associated with the greatest 
relative risk.6,7,14,15 All the patients who developed symptomatic 
hyperlactataemia in this study were on a stavudine-
containing regimen; 8 patients in the entire clinic were on a 
stavudine/didanosine combination and, of these, 3 developed 
symptomatic hyperlactataemia, confirming the long experience 
of severe mitochondrial toxicity with this combination.
The risk of symptomatic hyperlactataemia may vary with 
demographics, being somewhat more common in black 
women, the obese and those with hepatitis B or C co-infection, 
but this is based on small case series.5,6,15 The role of female 
gender and obesity as potential predisposing factors may 
be applicable to our study population. A study comparing 
metabolic side-effects of ART in men and women showed 
59% of women were of Haitian or African origin. After 
adjusting for age, CD4 cell count, viral load, time since HIV 
diagnosis, history of AIDS-defining illnesses and year of ART 
initiation, no sex/gender differences were observed in the 
overall incidence of hyperglycaemia, hypercholesterolaemia 
and lipodystrophy. Women did, however, have a significantly 
higher risk of developing lactic acidosis than men (5.2% v. 
2.2%; p=0.0009).17 Similarly, there is a higher incidence of 
symptomatic hyperlactataemia in women compared with 
men in our series, with a relative risk of 3.27 for females. This 
figure is higher than that found in another review where the 
relative risk was 2.5.5 The median body weight among those 
who developed symptomatic hyperlactataemia was 72 kg, 
but the retrospective nature of this record review precludes 
further analysis of the significance of this finding. It has been 
suggested that being overweight may be a risk factor.14,18 It 
is postulated that being overweight, or weight gain, may 
predispose to hepatic steatosis, compromising the liver’s ability 
to clear excess lactate.14 Of patients attending the clinic, 92% are 
black, the rest being white, coloured or of Indian descent.19 A 
single case was seen in a white patient, making analysis of race 
as a risk factor difficult.
Pre-existing chronic hepatitis B and C infection have been 
identified as risk factors for milder, asymptomatic forms 
of nucleoside-analogue-related liver toxicity, but a clear 
association with symptomatic hyperlactataemia has not been 
established.20 It is not routine practice to screen for hepatitis 
B or C infection in this clinic as the prevalence of hepatitis 
C infection in our indigenous population is extremely low, 
although one case from our clinic had documented infection 
and was one of the fatalities. The prevalence of chronic 
Table II. Laboratory parameters at time of symptomatic hyperlactataemia
Investigation        No. of patients                  Median (IQR)           Mean (SD)   Range                   Normal range
First venous         35   8.29            8.99   5.23 - 14.53   0.6 - 2.45
lactate (mmol/l)    (6.46 - 11.21)           (2.82)
Peak venous        35   7.65            8.36   5.21 - 14.53   0.6 - 2.45
lactate (mmol/l)    (6.21 - 10.1)           (2.56)
pH         17   7.3            7.29   7.1 - 7.4    7.35 - 7.45
     (7.28 - 7.3)           (0.07)
Bicarbonate         28   16            15.6   5 - 23    18 - 28
(mmol/l)     (13 - 19.5)            (4.9)
Urea         28   3.75            7.95    2 - 78    2.6 - 7
(mmol/l)     (2.6 - 6.25)           (14.5)
Creatinine        28   67            130.5    50 - 1 567   60 - 120
(µmol/l)     (54 - 100)            (283)
AST         30   50            71.8    19 - 362    5 - 40
(U/l)     (41 - 78)            (63.8)
ALT         30   49.5            63.5    16 - 167    5 - 40
(U/l)     (31 - 85)            (42.7)
Amylase         25   121            247.6    59 - 1 441   28 - 110
(U/l)     (87 - 218)            (335.0)
Glucose         14   5.6            7     3.9 - 13.3    4.1 - 11.1
(mmol/l)     (4.5 - 9)            (3.1)
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hepatitis B infection in the clinic population, and its influence 
on the development of this complication, is an area for further 
research. Renal and hepatic laboratory abnormalities (Table II) 
in our patients at the time of diagnosis were similar to those in 
other studies.6,14
Studies have confirmed that asymptomatic hyperlactataemia 
in patients on ART does not predict for development of 
symptomatic hyperlactataemia.21,22 From these data, there 
may be a few laboratory or clinical indicators that clinicians 
can utilise to detect the condition early, as it appears to be 
insidious in onset and progressive in nature, with nonspecific 
symptoms. The most powerful tool at present is a health 
care practitioner who can diagnose and intervene early with 
minimal investigation.
Gastrointestinal complaints were by far the most common 
symptoms reported. In many patients, these symptoms were 
documented at clinic visits before the diagnosis of symptomatic 
hyperlactataemia. ‘Easy to detect’ clinical signs are unexplained 
weight loss and neuropathy. It is imperative that weight is 
routinely monitored. Weight loss, in 83% of our patients, has 
been documented in other series14 and, when it occurs, must 
be quickly investigated. This is attainable in resource-limited 
settings. Another potential sign is the onset of neuropathy 
after commencement of ART. In our clinic, 37% of patients 
had neuropathy at the time of diagnosis. Early switching to 
zidovudine may prevent the more severe manifestations of 
mitochondrial toxicity.
Therapeutic intervention for symptomatic hyperlactataemia 
included the immediate discontinuation of all antiretroviral 
agents at the time of diagnosis or strong suspicion thereof. If 
admitted to the hospital, supportive care was offered in the 
form of intravenous fluids, glucose and bicarbonate solution. 
In patients with suspected sepsis, empirical antibiotics were 
administered. Those with pancreatic dysfunction were kept 
nil per os until pancreatic function normalised, clinicians 
having the impression that cessation of enteral feeding 
enhanced their recovery. Others have described the use of total 
parenteral nutrition as part of their care.14 Haemodialysis was 
performed on 2 patients in intensive care, and both died. In our 
experience, patients who progress rapidly to multiple organ 
dysfunction/failure carry the worst prognosis.
The mortality rate in our group was 21%, which appears to 
be less than that reported by other centres, where mortality 
from symptomatic hyperlactataemia ranged from 25% to 
60%.9,14,16 It is noteworthy that of those treated as outpatients, 
100% survived.
Confounding factors that may have introduced bias in 
our survival data may have been the retrospective nature 
of this record review, partial data collection, interpretation 
biases and incomplete medical records. Bias could also have 
been introduced because some patients with symptomatic 
hyperlactataemia might have been misdiagnosed and 
subsequently died; some patients might have been admitted to 
other hospitals in the area and died, or died at home without 
our knowledge. However, a recently completed drive within 
the clinic to trace defaulters and patients who died, showed 
that most patients who died did so shortly after commencing 
ART.23 This suggests that immune suppression, immune 
reconstitution syndromes and possibly acute ART toxicity were 
responsible for the vast majority of deaths, rather than the 
more chronic toxicity of mitochondrial damage.
Conclusion
Simple clinical measures, such as detection of symptomatic 
neuropathy and weight loss, may alert the clinician to 
impending symptomatic hyperlactataemia, particularly 
in women and overweight patients. Aggressive clinical 
investigation of unintentional weight loss is justified in people 
on ART. Early diagnosis of symptomatic hyperlactataemia 
allows safe outpatient care and uninterrupted switching of 
ART regimens in some. Co-treatment with stavudine and 
didanosine carries a very high risk for this complication, and 
should not be used.
Ideally, replacing stavudine with an equally potent NRTI 
in first-line therapy that is easy to use, has a better safety 
profile and is affordable in South Africa, would decrease 
mitochondrial toxicity syndromes significantly. Tenofovir is 
currently under registration review and, along with abacavir, 
is being considered as an alternative. However, both drugs are 
significantly more expensive and carry alternative toxicities.
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